Industry experts from across 100 countries will descend on Riyadh this December for launch event of most comprehensive pharma ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced its business update and financial ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3 - TransCon CNP NDA submission for achondroplasia planned for Q1 2025 ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Welcome to Tarsus’ Third Quarter 2024 Financial Results ...

Mavorixafor was generally well tolerated as a monotherapy and in combination with G-CSF, with no drug-related serious adverse ...

Amphastar Pharmaceuticals, Inc. - 10-Q, Quarterly Report 06.11. Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 ...

Some are more clear than others. President-elect Donald Trump ’s nomination of Robert F. Kennedy Jr. as head of the ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon. And welcome to Cumberland Pharmaceuticals Third ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced its business update and financial results for the first nine months of 2024. TELLOMAK ...

The live webcast and accompanying slide presentation will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. A live Q&A will follow the ...